Pelech et al.: May 2020, over 90% uninfected in Vancouver Canada had antibody reactivity against spike (S), receptor-binding domain (RBD), N-terminal domain (NTD), nucleocapsid (N) protein SARS CoV-2
by Paul Alexander
Elegant study by Pelech, Majdoubi, Lavoie et al. in Vancouver British Columbia showed us early 2020 that this was never NOVEL, and we had immunity at some level; no lockdowns or VAX was needed!
SARS-CoV-2 was circulating way before January 2020 or December 2019. Our immune systems had experience with it.
This study is another example. This study should anger people when you read it as to the findings.
The fact that the nucleocapsid protein as one example, highly conserved, little if any mutation, showed antibody reactivity from SARS-CoV-2, showed that there was prior exposure and infection at some level and recovery and natural immunity.
Yet this study was swept under the rug!
I continue to argue that vaccine was only to be offered, never to be mandated, and still I argued then not needed, just strongly protect the vulnerable elderly etc. in our societies and leave the rest of society alone, unfettered, and allow us to get to natural immunity and herd immunity, naturally and harmlessly. Allow children to develop natural innate immunity (first line of defense) that would broadly protect them against pathogen (glycosylated viruses). Allow their innate antibodies to train their innate immune system (and natural killer cells, NK cells) so that children can handle a broad range of pathogen as they get older and for their immune system to distinguish between ‘self’ from ‘non-self’ components (to limit or stop auto-immune reactivity).
Preexisting cross-reactivity to SARS-CoV-2 occurs in the absence of prior viral exposure. However, this has been difficult to quantify at the population level due to a lack of reliably defined sero-reactivity thresholds. Using an orthogonal antibody testing approach, we estimated that about 0.6% of non-triaged adults from the greater Vancouver, Canada, area between May 17 and June 19, 2020, showed clear evidence of a prior SARS-CoV-2 infection, after adjusting for false-positive and false-negative test results. Using a highly sensitive multiplex assay and positive/negative thresholds established in infants in whom maternal antibodies have waned, we determined that more than 90% of uninfected adults showed antibody reactivity against the spike protein, receptor-binding domain (RBD), N-terminal domain (NTD), or the nucleocapsid (N) protein from SARS-CoV-2.
This sero-reactivity was evenly distributed across age and sex, correlated with circulating coronaviruses' reactivity, and was partially outcompeted by soluble circulating coronaviruses' spike. Using a custom SARS-CoV-2 peptide mapping array, we found that this antibody reactivity broadly mapped to spike and to conserved nonstructural viral proteins. We conclude that most adults display preexisting antibody cross-reactivity against SARS-CoV-2, which further supports investigation of how this may impact the clinical severity of COVID-19 or SARS-CoV-2 vaccine responses.